WO1997034000A1 - Expression and secretion of heterologous polypeptides from caulobacter - Google Patents
Expression and secretion of heterologous polypeptides from caulobacter Download PDFInfo
- Publication number
- WO1997034000A1 WO1997034000A1 PCT/CA1997/000167 CA9700167W WO9734000A1 WO 1997034000 A1 WO1997034000 A1 WO 1997034000A1 CA 9700167 W CA9700167 W CA 9700167W WO 9734000 A1 WO9734000 A1 WO 9734000A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- layer
- caulobacter
- rsaa
- gene
- Prior art date
Links
- 241000863012 Caulobacter Species 0.000 title claims abstract description 105
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 87
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 68
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 65
- 230000028327 secretion Effects 0.000 title description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 148
- 101710099182 S-layer protein Proteins 0.000 claims abstract description 68
- 101710168515 Cell surface glycoprotein Proteins 0.000 claims abstract description 67
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 64
- 210000004027 cell Anatomy 0.000 claims abstract description 62
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 37
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims abstract description 14
- 230000001580 bacterial effect Effects 0.000 claims abstract description 11
- 238000003780 insertion Methods 0.000 claims description 84
- 230000037431 insertion Effects 0.000 claims description 84
- 150000001413 amino acids Chemical class 0.000 claims description 60
- 241000010804 Caulobacter vibrioides Species 0.000 claims description 38
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 abstract description 46
- 102000037865 fusion proteins Human genes 0.000 abstract description 46
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 abstract description 20
- 230000000890 antigenic effect Effects 0.000 abstract description 5
- 239000010410 layer Substances 0.000 description 88
- 101100149558 Caulobacter vibrioides (strain ATCC 19089 / CB15) rsaA gene Proteins 0.000 description 60
- 235000018102 proteins Nutrition 0.000 description 53
- 108020004414 DNA Proteins 0.000 description 52
- 235000001014 amino acid Nutrition 0.000 description 51
- 238000000034 method Methods 0.000 description 51
- 229940024606 amino acid Drugs 0.000 description 48
- 239000013612 plasmid Substances 0.000 description 39
- 230000004927 fusion Effects 0.000 description 28
- 241000894006 Bacteria Species 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 101150096844 rsaA gene Proteins 0.000 description 21
- 238000012217 deletion Methods 0.000 description 15
- 230000037430 deletion Effects 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 238000010276 construction Methods 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000002703 mutagenesis Methods 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108010052285 Membrane Proteins Proteins 0.000 description 10
- 102000018697 Membrane Proteins Human genes 0.000 description 10
- 108090000157 Metallothionein Proteins 0.000 description 10
- 108010082913 S-layer proteins Proteins 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 229910052793 cadmium Inorganic materials 0.000 description 9
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 102000003792 Metallothionein Human genes 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 238000003119 immunoblot Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000013505 freshwater Substances 0.000 description 7
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000003252 repetitive effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 108010059892 Cellulase Proteins 0.000 description 5
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 5
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 5
- 108010000916 Fimbriae Proteins Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940106157 cellulase Drugs 0.000 description 5
- 150000002739 metals Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 101100060519 Homo sapiens CNR2 gene Proteins 0.000 description 4
- 241001620960 Pseudomonas aeruginosa PAK Species 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 101000664352 Caulobacter vibrioides (strain ATCC 19089 / CB15) S-layer protein Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 229920001131 Pulp (paper) Polymers 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 101150113191 cmr gene Proteins 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 101150025220 sacB gene Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000002344 surface layer Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003171 anti-complementary effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000004065 wastewater treatment Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FOWNDZJYGGTHRO-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-aminobutanedioic acid Chemical group NCC(O)=O.OC(=O)[C@@H](N)CC(O)=O FOWNDZJYGGTHRO-DKWTVANSSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241001409861 Caulobacter vibrioides CB15 Species 0.000 description 1
- 241000186320 Cellulomonas fimi Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000190831 Chromatium Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 108700023863 Gene Components Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101900269906 Infectious hematopoietic necrosis virus Glycoprotein Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 108010036940 Levansucrase Proteins 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710183296 Surface layer protein Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- PLZFHNWCKKPCMI-UHFFFAOYSA-N cadmium copper Chemical compound [Cu].[Cd] PLZFHNWCKKPCMI-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000004076 pulp bleaching Methods 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000007668 pye medium Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 241001507086 salmonid fish Species 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000034005 thiol-disulfide exchange Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- This invention relates to the expression and secretion of heterologous peptides, from Caulobacter wherein the heterologous polypeptide is fused with the surface layer protein (S-layer protein) of the bacterium, or a portion of the S-layer protein.
- S-layer protein surface layer protein
- Bacterial surface proteins have been used as carriers for foreign (heterologous) polypeptides (particularly in Salmonella and E. coli) for various purposes, including the development of live vaccines.
- the heterologous material is expressed as a fusion product with a surface protein of the bacterium.
- the use of such surface proteins as a vehicle for expression and/or presentation of heterologous polypeptides has been limited by the characteristics of a particular surface protein.
- the lipopolysaccharide layer of a bacterium which tends to stimulate a strong immune response, covers the integral outer membrane proteins of the organism and potentially affects efficient presentation of a cloned epitope.
- the surface protein is functional (for example, as part of a filamentous portion of a bacterial cell surface) there will be limited opportunities to express a fusion product and still retain the surface protein's function.
- the organisms that have been used for these purposes have been chosen because of the advantages presented in respect of the organism's relationship to its host.
- Many genera of bacteria assemble layers composed of repetitive, regularly aligned, proteinaceous sub-units on the outer surface of the cell. These layers are essentially two-dimensional paracrystalline arrays, and being the outer molecular layer of the organism, directly interface with the environment . Such layers are commonly known as S-layers and are found on members of every taxono ic group of walled bacteria including Archaebacteria; Chla ydia; Cyanobacteria; Acinetobacter
- an S-layer will be composed of an intricate, geometric array of at least one major protein having a repetitive regular structure.
- the S-layer protein is synthesized by the cell in large quantities and the S-layer completely envelopes the cell and thus appears to be a protective layer.
- Caulobacter are natural inhabitants of most soil and freshwater environments and may persist in waste water treatment systems and effluents.
- the bacteria alternate between a stalked cell that is attached to a surface, and an adhesive motile dispersal cell that searches to find a new surface upon which to stick and convert to a stalked cell.
- the bacteria attach tenaciously to nearly all surfaces and do so without producing the extracelluar enzymes or polysaccharide "slimes" that are characteristic of most other surface attached bacteria. They have simple requirements for growth.
- the organism is ubiquitous in the environment and has been isolated from oligotrophic to mesotrophic situations.
- Caulobacters are known for their ability to tolerate low nutrient level stresses, for example, low phosphate levels. This nutrient can be limiting in many leachate waste streams, especially those with high levels of iron or calcium.
- antisera raised against the S-layer protein of C. crescentus strain CB15 reacts with S-layer proteins from other Caulobacter (see: Walker, S.G. et al (1992) [supra]) .
- All S-layer proteins isolated from Caulobacter may be substantially purified using the same extraction method (pH extraction) which would not be expected to be a general purpose method for other bacterial membrane or surface associated proteins.
- All strains appear to have a polysaccharide reactive with antisera reactive against CB15 lipopolysaccharide species which appears to be required for S-layer attachment (see: Walker, S.G. et al (1992) [supra] ) .
- the S-layer elaborated by freshwater isolates of Caulobacter are visibly indistinguishable from the S-layer produced by Caulobacter crescentus strains CB2 and CB15.
- the S-layer proteins from the latter strains have approximately 100,000 m.w. although sizes of S-layer proteins from other species and strains will vary.
- the protein has been characterized both structurally and chemically. It is composed of ring-like structures spaced at 22nm intervals arranged in a hexagonal manner on the outer membrane.
- the S-layer is bound to the bacterial surface and may be removed by low pH treatment or by treatment with a calcium chelator such as EDTA.
- a heterologous polypeptide as a fusion product with the S- layer protein of Caulobacter provides advantages not previously seen in systems using organisms such as E. coli and Salmonella where fusion products of other kinds of surface proteins have been expressed. All known Caulobacter strains are believed to be harmless and are nearly ubiquitous in aquatic environments. In contrast, many Salmonella and E. coli strains are pathogens. Consequently, expression and secretion of a heterologous polypeptide using Caulobacter as a vehicle will have the advantage that the expression system will be stable in a variety of outdoor environments and may not present problems associated with the use of a pathogenic organism.
- Caulobacter are natural biofilm forming species and may be adapted for use in fixed biofilm bioreactors.
- the quantity of S-layer protein that is synthesized and is secreted by Caulobacter is high, reaching 12% of the cell protein.
- the unique characteristics of the repetitive, two-dimensional S-layer would also make such bacteria ideal for use as an expression system, or as a presentation surface for heterologous polypeptides. This is desirable in a live vaccine to maximize presentation of the antigen or antigenic epitope.
- use of such a presentation surface to achieve maximal exposure of a desired polypeptide to the environment results in such bacteria being particularly suited for use in bioreactors or as carriers for the polypeptide in aqueous or terrestrial outdoor environments.
- C-terminal region of the Caulobacter S-layer protein is essential for secretion of the S-layer protein.
- the inventors have determined that the 3' region of the gene which encodes the C-terminal region of the S-layer protein is conserved among different strains of Caulobacter.
- This invention provides a method of expressing and presenting to the environment of a Caulobacter. a polypeptide that is heterologous to the S-layer protein of the Caulobacter, which comprises inserting a coding sequence for the heterologous polypeptide in-frame into a S-layer protein gene of Caulobacter. or a portion of said S-layer protein gene, whereby the polypeptide is expressed and secreted by the Caulobacter as a chimeric protein comprising the heterologous protein and all or part of the S-layer protein.
- This invention provides a DNA construct for the aforemention chimeric protein, and a bacterium comprising such a DNA construct, wherein the DNA construct encodes all or part of a S-layer protein, and one or more in-frame sequences encoding one or more heterologous proteins.
- This invention provides a DNA construct comprising one or more restriction sites for facilitating insertion of DNA into the construct and, DNA encoding at least the 82 C-terminal amino acids of Caulobacter S-layer protein.
- the C-terminal amino acids are or correspond to amino acids 944 or 945-1026 of the RsaA protein of C. crescentus.
- This invention provides a DNA construct comprising DNA encoding a heterologous polypeptide sequence not present in a Caulobacter S-layer protein upstream from and in-frame with DNA encoding at least the 82 C-terminal amino acids of Caulobacter S-layer protein.
- the C-terminal amino acids are or correspond to amino acids 944 or 945- 1026 of the rsaA protein of C. crescentus.
- This invention also provides a secreted protein obtained from the cell surface or cell medium of a Caulobacter cell expressing the aforementioned DNA constructs wherein the secreted protein comprises the heterologous polypeptide and at least the 82 C-terminal amino acids of a Caulobacter S-layer protein.
- the C-terminal amino acids are or correspond to amino acids 944 or 945-1026 of the RsaA protein of C. crescentus.
- Figure 1 is the sequence of a Carrier cassette which may be cloned into the Pstl/BamHI site of pUC9 to deliver a gene sequence of interest to sites within a Caulobacter crescentus S-layer protein (rsaA) gene (SEQ ID NO:l) .
- rsaA Caulobacter crescentus S-layer protein
- Figure 2 is a restriction map of a plasmid based promoter-less version of the rsaA gene (pTZ18U:rsaA ⁇ ,P) containing restriction sites and which may be used to accept heterologous DNA of interest .
- Figure 3 is the nucleotide sequence of linker BamHI-
- plasmid pUC9B (pUC7165K) , which may be used for mutagenesis at sites created in rsaA by a specific or non-specific endonuclease.
- Figure 4 is the nucleotide sequence a linker BamHI-
- 6571K (SEQ ID NO:4; and SEQ ID NO:5) carried in plasmid pTZ19 (pTZ6571K) which may be used for mutagenesis at sites created in rsaA by a specific or non-specific endonuclease.
- Figure 5 is a map of insertion events at TaqI sites in the rsaA gene identified by amino acid number of the insertion site in the S-layer protein and scored according to whether the S-layer is produced in the modified organism.
- Figure 6 shows the complete nucleotide sequence of the C. crescentus S-layer (rsaA) gene (SEQ ID NO:6) and the predicted translational product in the single letter amino acid code.
- the -35 and -10 sites of the promoter region as well as the start of transcription and the Shine-Dalgarno sequence are indicated.
- Partial amino acid sequences determined by Edman degradation of rsaA protein and of sequenced peptides obtained after cleavage with V8 protease are indicated by contiguous underlining.
- the putative transcription terminator palindrome is indicated with arrowed lines.
- the region encoding the glycine-aspartate repeats is indicated by underlined amino acid code letters. This region includes five aspartic acids that may be involved in the binding of calcium ions.
- Figure 7 is a bar graph showing the approximate location by amino acid block of 54 permissive sites in the rsaA gene corresponding to TaqI, HinPI, Acil, and Mspl sites described in Example 3.
- Figure 8 is a portion of an amino acid sequence (SEQ ID NO: 8) from P. aeruginosa PAK pilin in which the 12 amino acid pilus peptide epitope referred to in Example 5 is identified by superscript numerals 1-12.
- Figure 9 is the nucleotide coding sequence and corresponding amino acid sequence (SEQ ID NO: 9) in respect of the 184 amino acid sequence corresponding to amino acids
- Figure 10 is the amino acid sequence of the synthetic cadmium binding peptide referred to in Example 4. The cadmium binding site is shown in the figure.
- Figure 11 shows locations of some of the sites in rsaA in which single and multiple copies of the pilus peptide described in Example 5 was expressed and secreted as part of a chimeric rsaA protein.
- Figure 12 shows a portion of pUC8 containing various C-terminal fragments of rsaA as described in Example 7.
- the preferred organism for use in this invention is Caulobacter. particularly C. crescentus. While similarity of the S-layer gene and S-layer secretion systems permits the use of any S-layer protein producing Caulobacter in this invention, C. crescentus strains CB2 and CB15 and variants of those strains which contain homologs of the gene encoding the 1026 amino acid paracrystalline S-layer protein described in: Gilchrist, A. et al . 1992. "Nucleotide Sequence Analysis Of The Gene Encoding the Caulobacter crescentus Paracrystalline Surface Layer Protein". Can. J. Microbiol. 38:193-208, are referred to in the examples described below.
- Caulobacter strains which either are incapable of forming an S-layer, including those which shed the S-layer protein upon secretion, may be used in this invention.
- Examples are the variants CB2A and CB15AKSac described in Smit, J. , and N. Agabian. 1984. "Cloning of the Major Protein of the Caulobacter crescentus Periodic Surface Layer: Detection and Other Characterization of the Cloned Peptide by Protein Expression Assays". J. Bacteriol. 160:1137-1145.; and, Edwards, P., and J. Smit. 1991. "A Transducing Bacteriophage for Caulobacter crescentus Uses the Paracrystalline Surface Layer Protein as Receptor". J. Bacteriol. 173 , 5568-5572. Examples of shedding strains are CB15Ca5 and CB15Cal0 described in Edwards and Smit
- a heterologous polypeptide referred to herein may be any peptide, polypeptide, protein or a part of a protein which is desired to be expressed in Caulobacter and which may be secreted by the bacterium.
- the heterologous polypeptide includes enzymes and other functional sequences of amino acids as well as ligands, antigens, antigenic epitopes and haptens.
- the size of the heterologous polypeptide will be selected depending upon whether an intact S-layer is to be produced in the Caulobacter or whether the chimeric protein to be recovered from the bacterial medium as described below.
- the cysteine content of the heterologous polypeptide and the capacity for formation of disulphide bonds within the chimeric protein will be kept to a minimum to minimize disruption of the secretion of the chimeric protein.
- the presence of cysteine residues capable of forming a disulphide bond which are relatively close together may not affect secretion.
- the following general procedure lays out courses of action and specifies particular plasmid vectors or constructions that may be used to accomplish fusion of an S-Layer protein with a polypeptide of interest.
- the following description uses the rsaA (S-layer) gene of C. crescentus as an example (see Figure 6 and SEQ ID NO:6) .
- the latter gene sequence is characterized in Gilchrist, A. et al (1992) [supra) .
- the general procedure involves the following steps and alternative courses of action.
- the practitioner will choose an appropriate region (or specific amino acid position) of the S-layer for insertion of a desired polypeptide.
- the practitioner will create a unique restriction site (preferably hexameric) in the rsaA (S-layer) gene at a position within the gene encoding that region (or corresponding to a specific amino acid) using either standard linker mutagenesis (regional) or site directed mutagenesis (specific amino acid) .
- the unique restriction site will act as a site for accepting DNA encoding the polypeptide of interest .
- the plasmid-based promoter-less version of the rsaA gene (pTZ18U:rsaA ⁇ P) shown in Figure 2 may be used because it contains an appropriate combination of 5' and 3' restriction sites useful for subsequent steps (see: Gilchrist, A. et al
- restriction site should not occur in rsaA. its carrier plasmid or the DNA sequence coding for the polypeptide of interest.
- a random linker mutagenesis approach is used to randomly insert a unique linker-encoded restriction site (preferably hexameric) at various positions in the rsaA gene.
- Sites for insertion of the linker are created using an endonuclease, either of a sequence specific nature (e.g. tetrameric recognition site restriction enzyme) or sequence non-specific nature (e.g. Deoxyribonuclease I [DNase I] ) .
- a particularly suitable method is the generalized selectable linker mutagenesis approach based on any desired restriction site of: Bingle, W.H. , and J. Smit.
- restriction endonucleases are used to create sites for subsequent insertion of a linker encoding a hexameric restriction site
- mutagenesis may also be done with a mixture of 3 different linkers incorporating appropriate spacer nucleotides in order to satisfy reading frame considerations at a particular restriction site (only 1 of the 3 linker insertions will be useful for subsequent acceptance of DNA encoding the polypeptide of interest) .
- DNase I only one linker is needed, but again only 1 of 3 linker insertions may be useful for accepting DNA encoding the polypeptide of interest depending on the position of the DNase I cleavage with respect to the 3 bases of each amino acid codon.
- a linker tagged with a marker is used to insert DNA of interest at a restriction site.
- BamHI sites are appropriate as sites for the introduction of DNA encoding a polypeptide of interest
- BamHI linkers tagged with a kanamycin-resistance gene for selectable linker mutagenesis may be used.
- One such 12-bp linker carried in plasmid pUC1021K was described by Bingle and Smit (1991) [Supra] . Two additional 15-bp linkers
- pUC7165K and pTZ6571K constructed for creating the other 2 possible translation frames within the linker insert itself are described in Figures 3 and 4 (SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; and, SEQ ID NO:5) .
- Any one of the above three kanamycin-resistance tagged BamHI linkers is suitable for mutagenesis at sites created in rsaA by DNase I.
- a mixture of all three linkers is preferably used for mutagenesis at sites created in rsaA by restriction enzyme digestion.
- the DNA encoding a polypeptide of interest is inserted into the sites en masse (the library of mutated rsaA genes may be manipulated as one unit) .
- the library is digested with the restriction enzyme specific for the newly-introduced linker encoded restriction site and ligated to a DNA fragment encoding the polypeptide of interest and carrying the appropriate complementary cohesive termini.
- the DNA specifying the polypeptide of interest can be prepared by a number of standard methods, which may include oligonucleotide synthesis of 2 anti- complementary strands, polymerase chain reaction (PCR) procedures, or addition of linkers whose termini are compatible with the introduced sites in rsaA to a suitably modified segment of DNA.
- standard methods which may include oligonucleotide synthesis of 2 anti- complementary strands, polymerase chain reaction (PCR) procedures, or addition of linkers whose termini are compatible with the introduced sites in rsaA to a suitably modified segment of DNA.
- the Carrier oligonucleotide shown in Figure 1 may be used.
- the Carrier is designed to accept DNA (including multiple copies and mixtures) prepared by PCR or annealed synthesized oligonucleotides and controls direction of insertion of the foreign segment into a rsaA gene through use of a promoterless drug resistance marker.
- the DNA of interest is first directionally cloned, if possible, using the Xhol, StuI, or Sail sites or non-directionally cloned using any one of the sites in the same orientation as a promoterless chloramphenicol resistance (CmR) gene.
- CmR chloramphenicol resistance
- the DNA of interest must be provided with the appropriate termini for cloning and spacer nucleotides for maintaining correct reading frame within the cassette and should not contain a Bglll site.
- the DNA of interest is recovered as a BamHI fragment tagged with a CmR gene.
- the bacterium eg. E. coli
- only those colonies of the bacterium (eg. E. coli) used for the gene modification steps that are recovered will be those carrying insertions of the desired DNA in the correct orientation, since the promoter on the plasmid is 5' to rsaA ⁇ P and the CmR gene.
- the carrier oligonucleotide also provides the opportunity to add DNA 5' or 3 ' to the DNA of interest at Sail. Xhol or StuI sites providing the DNA of interest does not contain any of these sites. This allows some control over spacing between rsaA sequences and the sequence of the DNA of interest.
- the rsaA genes carrying the DNA of interest in the correct orientation is excised from the plasmid (eg. from the pTZ18U:rsaA ⁇ P plasmid) and is transferred to a suitable vector providing a promoter recognized by Caulobacter.
- suitable vectors include pWB9 or pWBlO (as described in Bingle, W.H., and J. Smit. 1990) .
- the DNA of interest should not contain the same restriction sites present in the vector.
- the latter vectors allow expression of rsaA hybrids in S-layer negative mutants of Caulobacter such as CB15KASac.
- heterologous polypeptides of up to about 60 (preferably less than 50) amino acids in a S-layer chimeric protein which will assemble as an S-layer on the cell surface.
- Single or multiple insertions of smaller polypeptides eg. 10-20 amino acids
- Some sites, as reported herein, are sensitive to even small insertions resulting in the chimeric protein being released into the medium. Release may also be deliberately effected by use of a shedding strain of Caulobacter to express the chimeric protein or by physical removal of the S-layer from whole cells.
- this invention permits the expression of quite large polypeptides (eg. about 200 amino acids) as part of the S- layer protein.
- the preceding methods describe insertion of linkers in-frame into an rsaA gene (eg. a promoterless version of the gene) .
- the sites that are introduced allow subsequent insertion of foreign DNA in-frame into the full length rsaA gene.
- This invention also includes the construction of chimeric S-layer protein genes and the resulting production of chimeric S-layer proteins wherein the S-layer gene component is highly modified by deleting large portions of that gene which reduces the amount of Caulobacter protein present in the secreted chimeric protein.
- the chimeric protein need only have the 82 amino acid C- terminal region of the S-layer protein to be secreted from the cell. Furthermore, use of the C-terminal region corresponding to about amino acids 850-1026 (or more) of RsaA not only permits the cell to transport the chimeric protein outside of the cell, but also promotes spontaneous aggregation of much of the secreted chimeric protein in the cell medium and formation of a macroscopic precipitate that may be collected with a course mesh or sheared to micron- sized particles which may be ideal for vaccine presentation. Yields of up to 250 mg. (dry weight) of protein per liter of cells may be possible.
- Sequence analysis of the 3' region of the S-layer genes from different strains of Caulobacter shows that the portion of the gene encoding the C-terminal region of the S-layer protein is highly conserved along with the immediate downstream non-translated and translated region. Sequence analysis of the S-layer genes and downstream regions in CB15 and CB2A (which are readily distinguishable strains) shows identical DNA sequences coding for the last 118 C-terminal amino acids of the S-layer protein and the downstream non-translated region. Sequencing of the next downstream translated gene to amino acid 97 of the gene product shows only a single base pair change between CB15 and CB2A, resulting in a conservative amino acid substitution in the translation product. Conservation of the C-terminal region of Caulobacter S-layer protein and associated coding regions shows that this invention may be carried out using any Caulobacter producing a S-layer protein.
- This invention may be practised as shown in the Examples by expression of modified S-layer genes borne on plasmids that are broad host range vectors capable of being expressed in Caulobacter.
- Such plasmids are readily constructed and introduced to Caulobacter by electroportation.
- the plasmid is maintained in the Caulobacter by antibiotic selection.
- Highly modified rsaA genes with attached heterologous sequences may also be introduced into Caulobacter on a plasmid that is not replicated by Caulobacter.
- homologous recombination of the incoming modified S-layer gene with the chromosome-resident copy of the S-layer gene in the cell will result in a gene rescue or transfer event.
- Various protocols for creating chromosomal insertions are set out in the Examples.
- the S-layer protein is synthesized in large quantities and has a generally repetitive sequence. This permits the development of systems for synthesis of a relatively large amount of heterologous material as a fusion product with an S-layer protein (chimeric protein) . It may be desirable to retain the chimeric protein as part of the bacterial cell envelope or, the fusion product may be separated from the organism, such as by the method described in: Walker, S.G., et al. 1992. "Isolation and Comparison of the Paracrystalline Surface Layer Proteins of Freshwater Caulobacters" ⁇ J. Bacteriol. 174:1783-1792. Alternatively, the Caulobacter strain that is used to express the fusion product may be derived from a strain such as CB15Ca5 that sheds its S-layer.
- This invention is particularly suited for use in a bioreactor systems.
- An example would be the use of a modified Caulobacter expressing a polypeptide having activity similar to that of a metallothionein in a bioreactor, to bind toxic metals in sewage, waste water etc.
- Caulobacters are ideal candidates for fixed-cell bioreactors, the construction of which is well known.
- An example of such a bioreactor is a rotating biological contactor.
- other bacteria are found in the environment that are capable of binding metals, they often do so by producing copious polysaccharide slimes that quickly plug filtration systems. In some cases, the bacteria are not surface-adherent or the bacteria do not show selectivity towards key toxic metals.
- bioreactors may be formed comprising a substrate and a single layer of cells adhered thereon, with the cells distributed at high density.
- substrates may be used such as a column of chemically derivatized glass beads or a porous ceramic material such as ceramic foam.
- Another advantageous application for this invention is in the production of batch cultures of modified Caulobacter wherein the S-layer protein is a fusion product with an enzyme.
- such Caulobacter could be grown in wood pulp suspensions at an appropriate juncture of the pulping process in order to provide for enzymatic decomposition of the wood-pulp structure (e.g. with an enzyme having an activity like xylanase or cellulase) .
- Such an application may permit more effective penetration of bleaching agents in the wood-pulp bleaching process thereby reducing the use of chlorine-based bleaching agents.
- Examples of enzymes that may be expressed as chimeric S-layer proteins include alkaline phosphatase (eg. by expression of the pho A gene of E. coli; see: Hoffman, C . S . , and Wright, A. 1985. "Fusions of Secreted Protein to Alkaline Phosphatase: An Approach for Studying Protein Secretion". Proc. Natl. Acad. Sci. U.S.A. 82:5107-5111; Bingle, W.H., et al. 1993.” An “All Purpose” Cellulase Reporter for Gene Fusion Studies and Application to the Paracrystalline Surface (S) -Layer Protein of Caulobacter crescentus” . Can.J.
- modified Caulobacter may be readily cultured in outdoor freshwater environments and would be particularly useful in fish vaccines.
- the two-dimensional crystalline array of the S- protein layer of Caulobacter which has a geometrically regular, repetitive structure, provides an ideal means for dense packing and presentation of a foreign epitope to an immune system in cases where the epitope is part of an intact S-layer in the bacterial cell surface.
- This invention also provides an efficient expression system for polypeptides that may be harvested in large quantities relatively free of contaminants and protein of Caulobacter origin.
- Expression of a heterologous polypeptide fused with sufficient C-terminal amino acids of the S-layer protein to promote secretion of the heterologous polypeptide results in the accumulation of large quantities of secreted protein in the cell medium.
- the chimeric protein does not have to be released from the cell surface.
- adjustment of the size of the S-layer protein portion can dictate whether the secreted chimeric protein is soluble or will precipitate in the cell medium.
- This embodiment may also be useful in cases where the Caulobacter is to express a foreign antigenic component and it is desired to minimize the amount of Caulobacter protein that is associated with the foreign antigen secreted by the Caulobacter.
- Example 1 Production of Permissive Insertion Sites in C.crescentus Using the restriction enzyme TagI. a partial digestion of the rsaA gene in pTZ18U:rsaA ⁇ P produced a group of linearized segments with random TaqI sites cleaved. The linearized segments were modified by use of the tagged linker mutagenesis procedure of Bingle and Smit (1991) [supra] , using the 12-bp BamHI linker carried in plasmid pUC102K discussed in the general procedure above. Those products that produced a full-length protein in E. coli were ultimately transferred to pWBI (a minor variation of pWB9 that is replicated by Caulobacter) , as described in the general procedure.
- TagI restriction enzyme
- the above-described five positive events represent cases where the 4-amino acid insertion is tolerated with no effect on the S-layer function.
- the S-layers of the modified Caulobacter were indistinguishable from a wild- type S-layer. Thus, they have a higher potential for tolerating the addition of more foreign peptide material than less characterized sites.
- 3 versions of the gene of interest representing each possible reading frame (using standard linker addition technology) , one may test each of these sites for suitability in expressing the desired activity.
- restriction enzymes other than TaqI such as Acil, HinPI or Mspl
- a larger library of BamHI insertions may be created.
- the plasmid-containing clone and relevant control strains were examined for the ability to bind several metals known to be bound by native metallothionein. This was done by growing the strains of bacteria in the presence of the metals at a concentration of 5ug/ml. After extensive washing of the cells to remove unbound metal, the cells were ashed by treatment at 500oC and the residue was dissolved in dilute nitric acid and examined for metal content by atomic absorption spectroscopy. The results from one round of data collection is shown in Table 1. In the case of cadmium and copper, an elevated level of bound metal is noted in the metallothionein-expressing strains. Table 1
- a library of 240 BamHI linker insertions was created using the procedures of Example 1. Of the 240 insertions, 45 target sites in the rsaA gene were made with TagI . 34 of the latter insertions were discarded because the clones contained deletions of rsaA DNA as well as the linker insertions. The remaining 11 resulted in 5 non-permissive and the 6 permissive sites described in Example 1. The remaining 195 insertions in the library were made using the enzymes HinPI, Acil. and Mspl to create target sites as outlined in Example 1. Of the latter 195 insertions, 49 permissive sites were located for a total of 55.
- Figure 7 illustrates the approximate location by restriction mapping of 54 permissive sites.
- the results show that sites that will accept 2-4 amino acids while still allowing the protein to be made and assembled into an S-layer are scattered up and down the protein. Furthermore, there is an unexpectedly high proportion of sites at which such insertions do not prevent expression and assembly of the S-layer.
- the results indicate that approximately 25-50% of in-frame linker insertions will be tolerated by the S-layer protein and the Caulobacter and that diverse regions of the protein will tolerate insertions.
- Caulobacter is an ideal candidate for expression of polypeptides fused with the S-layer and the presence of multiple permissive sites extending along the rsaA gene will permit the insertion of a plurality of the same or different peptides into the same RsaA protein molecule and expressed on the surface of a single Caulobacter.
- Example 3 The results described for Example 3 indicated that it would be possible to insert metallothionein at multiple places in the RsaA protein and thereby enhance the metal binding capacity of such a transformed Caulobacter.
- Example 2 when the procedures of Example 2 were repeated to insert the metallothionein coding sequence into others of the 54 permissive sites identified in the preceding Example in each case, the transformed Caulobacter did not secrete a chimeric protein and did not synthesize an S-layer.
- the transformed Caulobacter of Example 2 was stable as long as the transformants were frozen immediately after isolation.
- the transformants deleted the metallothionein portion of the S-layer and the S-layer protein returns to its normal size.
- the coding sequence for the 12-amino acid pilus peptide epitope lacking cysteine residues from Pseudomonas aeruginosa PAK pilin was inserted at the sites using the procedures described above and employing the Carrier cassette shown in Figure 1. Positioning of the added DNA between the first Bam HI site and the Bgl II site permitted use of the latter site for making repeated insertions of DNA.
- the coding sequence for the peptide shown in Figure 8, including both cysteine residues was also inserted in separate experiments.
- DNA coding for the peptide shown in Figure 8 was prepared by oligonucleotide synthesis of two anti- complementary strands.
- the transformed bacteria were screened for both production and presentation of the epitopes by the transformed Caulobacter by using standard Western immunoblot analysis (see: Burnette, W. N. 1981. "Western Blotting; Electrophoretic Transfer of Protein from Sodium Dodecyl-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection Antibody and Radioiodinated Protein A". Analytical Biochemistry 112:195- 203) and by colony immunoblot tests in which the cells were not disrupted (see: Engleberg, N.C., et al . 1984.
- Bacterial surface proteins from organisms other than Caulobacter described in the prior art are generally not known to accept polypeptides larger than about 60 amino acids within the structure of the surface protein.
- the procedures of the preceding Example were carried out in order to insert the coding sequence of a 109 amino acid epitope from IHNV virus coat glycoprotein at insertion sites identified in the preceding Example.
- the IHNV epitope was prepared by PCR and had the portion of the sequence shown in Figure 9 (SEQ ID NO:9) which is equivalent to amino acid residues 336-444 of the IHNV sequence described in: Koener, J.F. et al . 1987.
- the IHNV insert contains a single cysteine residue and is an extremely large insert for successful expression as a fusion product with a bacterial surface protein.
- an additional linker insertion was created at amino acid position 95 of the native gene (i.e. this gene carried its own promoter) using the same methodology. All five in-frame BamHI linker insertion sites were inserted in the rsaA so that the nucleotides of the linker DNA were read in the reading frame GGA/TCC ( Figure 12) .
- LacZa:rsaA fusion proteins can be produced in C. crescentus using the lacZa transcription/translation initiation signals when introduced on appropriate plasmid vectors or direct insertion into the chromosome (see: W.H. Bingle, et al . 1993. "An Ail-Purpose Cellulase Reporter for Gene Fusion Studies and Application to the Paracrystalline Surface (S) - Layer Protein of Caulobacter crescentus. " Can. J. Microbiol. 39:70-80) .
- Both types of constructions result in the production of proteins that are secreted in Caulobacter strains as highly modified RsaA proteins.
- the gene segments can also facilitate the secretion of heterologous polypeptides by insertion or fusion of appropriate DNA sequences at the unique BamHI site that exists in each of the constructions. The following describes specific methods for doing so to create chimeric proteins capable of secretion in C. crescentus.
- a) Insertion of a single copy of the desired gene segment Depending upon the length of the gene segment, two methods of construction may be used. For segments of up to about 30 amino acids, two oligonucleotides of appropriate sequence are chemically synthesized, annealed by mixing, heating and slow cooling and then ligated into the Carrier cassette. The oligonucleotides will also contain additional base pairs that recreate "sticky ends" of appropriate restriction endonuclease sites at each end of the duplex DNA that results from the annealing process. For longer segments, PCR is used to amplify a region of a target DNA sequence.
- Oligonucleotides are synthesized that have sequence complementary to the boundaries of the desired sequence and which contain additional base pairs that recreate a "sticky end" of an appropriate restriction endonuclease site.
- oligonucleotides are made to produce products with the appropriate restriction endonuclease site for directional cloning into the Carrier cassette. PCR amplification of the desired sequence is then done by standard methods.
- the sticky ends prepared must be appropriate for an Xhol site at the 5' terminus of the desired DNA sequence and StuI or Sail sites at the 3' terminus; this places the desired gene segment in the correct orientation within the Carrier cassette. Reading frame continuity is maintained by appropriate design of the oligonucleotides used for the PCR step.
- the Carrier cassette also allows production of multiple insert copies.
- a Bglll site in the cassette is restored after removal of the promoterless antibiotic resistance gene; that site can be used to insert an additional copy of the Carrier/desired sequence insertion, using the terminal BamHI sites, because the "sticky ends" produced by both BamHI and Bglll are the same.
- This "piggy-back" insertion still maintains the correct reading frame throughout the construction. Any number of additional cycles of "piggy-backing" can be done because the BamHI/Bglll ligation results in sequence which is no longer a substrate for either enzyme.
- the result is the production of cassettes of multiple copies of the desired sequence which can be transferred to appropriately modified S-layer protein genes with the same ease as a single copy.
- An additional feature of this method is that different heterologous sequences can be paired together in this multiple copy cassette with the same ease as multiple copies of the same heterologous sequence.
- Example 7a Insertion of an 109 amino acid segment of the IHNV surface glycoprotein to Carrier cassette.
- IHNV Infectious Hematopoietic Necrosis Virus
- Example 7b Insertion of an 184 amino acid segment of the IHNV surface glycoprotein to Carrier cassette .
- Example 7c Insertion of single and multiple copies and an epitope of the Pseudomonas aeruginosa PAK pilus gene to Carrier cassette.
- Oligonucleotides were constructed to code for the pilus epitope described in Example 5, which corresponds to a sequence at the extreme C-terminus of the pilus protein.
- Example 7d Fusion of Carrier/109 AA and 184 IHNV segments to C-terminal rsaA segment AA782-1026.
- Example 7e Fusion of Carrier/109 AA and 184 AA IHNV segments to C-terminal rsaA segment AA905-1026.
- Example 7f Fusion of Carrier/109 AA and 184 AA IHNV segments to C-terminal rsaA segment AA944-1026.
- Example 7g Fusion of Carrier/3x Pilus Epitope segment to C-terminal rsaA segment AA782-1026. This was done using the Carrier cassettes described in Example 7c above and the AA782-1026 rsaA C-terminal Segment Carrier plasmid described above.
- fusions described in examples 7d-7g were expressed in Caulobacter.
- expression and secretion of the chimeric S-layer protein was detected by Western immunoblot analysis of electrophoretic gels of the cell culture supermutant employing the monoclonal antibody for each of the polypeptide epitopes.
- the transporter signal for secretion from Caulobacter must be in the C-terminal region of amino acids 945-1026 of the S-layer protein as all chimeric proteins in the examples were secreted.
- C. crescentus strain CB2A and strain CB15aKSac fulfil this requirement. If it is important to ensure that all fusion protein is no longer attached to the cell surface, the use C. crescentus strains CB15Ca5KSac or CB15Cal0KSac are appropriate. These strains have additional mutations that result in the loss of the production of a specific species of surface lipopolysaccharide that has been demonstrated to be involved with the surface attachment of native S-layer protein as a 2-dimensional crystalline array (see: Walker S.G. et al 1994. "Characterization of Mutants of C. crescentus Defective in Surface Attachment of the Paracrystalline Surface Layer". J. Bacteriol. 176:6312- 6323) . Most often with the highly modified versions of the S-layer gene, this precaution is not necessary since virtually all regions of the gene that may have a role in the attachment process have been removed.
- a) Preparation of amplified segment with appropriate ends is carried out in a manner similar to that described part A(l) (a) above. Oligonucleotides are designed and synthesized such that they will anneal to appropriate regions of the desired heterologous DNA and also contain "sticky ends" of appropriate sequence and frame so that the resulting PCR product can be directed inserted into appropriate modified S-layer genes.
- Example 7h Insertion of the 109 AA IHNV segment into rsaA ( ⁇ AA95-782) and insertion of the 109 AA IHNV segment into rsaA( ⁇ AA188-782) is carried out as in Examples 7d-7g above. Expression of the desired genetic construction in appropriate C. crescentus strains is done using the procedures outlined in part A(3) above.
- the fusion of the Carrier cassette with appropriate heterologous DNA segments to a C-terminal S-layer protein segment plasmid results in a pUC8-based plasmid that is not maintained in Caulobacter. Selection for the antibiotic marker on the plasmid results in detection of the rescue events. Most commonly these are single crossover homologous recombination events. The result is a direct insertion of the entire plasmid into the chromosome. Thus the resident copy of the S-layer gene remains unchanged as well as the incoming highly modified S-layer gene. In such cases it may be desirable to use Caulobacter strains in which the resident S-layer gene is inactivated in known ways.
- C. crescentus strain CB15AKSac this strain has an antibiotic resistance gene cassette introduced at a position in the S-layer gene about 25% of the way from the 5' terminus.
- Example 9 (Transfer to the native S-layer gene chromosomal site as a double crossover event) .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20194/97A AU726384B2 (en) | 1996-03-12 | 1997-03-10 | Expression and secretion of heterologous polypeptides from caulobacter |
EP97908090A EP0888454A1 (en) | 1996-03-12 | 1997-03-10 | Expression and secretion of heterologous polypeptides from caulobacter |
JP9532138A JP2000506020A (en) | 1996-03-12 | 1997-03-10 | Expression and secretion of heterologous polypeptides from Caulobacter |
US09/142,648 US6210948B1 (en) | 1992-06-09 | 1997-03-10 | Expression and secretion of heterologous polypeptides from caulobacter |
IL12610197A IL126101A0 (en) | 1996-03-12 | 1997-03-10 | Expression and secretion of heterologous polypeptides from caulobacter |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89536792A | 1992-06-09 | 1992-06-09 | |
US08/194,290 US5500353A (en) | 1992-06-09 | 1994-02-09 | Bacterial surface protein expression |
US08/614,377 US5976864A (en) | 1992-06-09 | 1996-03-12 | Expression and secretion of heterologous polypeptides from caulobacter |
US08/614,377 | 1996-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997034000A1 true WO1997034000A1 (en) | 1997-09-18 |
Family
ID=56289744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1997/000167 WO1997034000A1 (en) | 1992-06-09 | 1997-03-10 | Expression and secretion of heterologous polypeptides from caulobacter |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1997034000A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000004170A1 (en) * | 1998-07-14 | 2000-01-27 | The University Of British Columbia | Cleavage of caulobacter produced recombinant fusion proteins |
WO2000049163A1 (en) * | 1999-02-19 | 2000-08-24 | The University Of British Columbia | Production of heterologous polypeptides from freshwater caulobacter |
US6777202B2 (en) * | 1996-02-01 | 2004-08-17 | Werner Lubitz | Recombinant expression of S-layer proteins |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2090549A1 (en) * | 1992-06-09 | 1993-12-10 | John Smit | Bacterial surface protein expression |
-
1997
- 1997-03-10 WO PCT/CA1997/000167 patent/WO1997034000A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2090549A1 (en) * | 1992-06-09 | 1993-12-10 | John Smit | Bacterial surface protein expression |
US5500353A (en) * | 1992-06-09 | 1996-03-19 | The University Of British Columbia | Bacterial surface protein expression |
Non-Patent Citations (7)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777202B2 (en) * | 1996-02-01 | 2004-08-17 | Werner Lubitz | Recombinant expression of S-layer proteins |
WO2000004170A1 (en) * | 1998-07-14 | 2000-01-27 | The University Of British Columbia | Cleavage of caulobacter produced recombinant fusion proteins |
WO2000049163A1 (en) * | 1999-02-19 | 2000-08-24 | The University Of British Columbia | Production of heterologous polypeptides from freshwater caulobacter |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5500353A (en) | Bacterial surface protein expression | |
US7186524B2 (en) | Method for exposing peptides and polypeptides on the cell surface of bacteria | |
CA2323634A1 (en) | Lactobacilli harboring aggregation and mucin binding genes as vaccine delivery vehicles | |
JP2008509682A (en) | Protein production method using YEBF | |
CA2811699C (en) | Fusion protein for secretory protein expression | |
US6861245B1 (en) | Production of heterologous polypeptides from freshwater caulobacter | |
US6210948B1 (en) | Expression and secretion of heterologous polypeptides from caulobacter | |
US20020009792A1 (en) | Expression and secretion of heterologous polypeptides from caulobacter | |
TWI241407B (en) | Live attenuated bacteria of the species actinobacillus pleuropneumoniae | |
US4853333A (en) | Production of rotavirus in yeast | |
JP4077878B2 (en) | Recombinant expression of S-layer-protein | |
JP2504723B2 (en) | Recombinant DNA, plasmid vector containing the same, and Escherichia coli harboring such recombinant DNA | |
WO1997034000A1 (en) | Expression and secretion of heterologous polypeptides from caulobacter | |
AU726384B2 (en) | Expression and secretion of heterologous polypeptides from caulobacter | |
AU767831B2 (en) | Expression and secretion of heterologous polypeptides from caulobacter | |
JPH0771492B2 (en) | Method for heat-inducible gene expression in Gram-positive bacteria | |
CA2237704A1 (en) | Cleavage of caulobacter produced recombinant fusion proteins | |
Bingle et al. | Definition of form and function for the S-layer of Caulobacter crescentus | |
zhou et al. | Development of a Conditional Plasmid for Gene Deletion in Non-Model Fusobacterium nucleatum strains | |
JP2004528039A (en) | Protease-deficient Caulobacter host cells | |
US20070212757A1 (en) | Expression System for the B Subunit of Cholera Toxin | |
US8435760B2 (en) | Systems for expression of heterologous proteins in M. capsulatus | |
WO1992014826A1 (en) | Bacillus thuringiensis-promoter | |
CN117616124A (en) | Chimeric gas vesicles and protein expression systems therefor | |
CA3224666A1 (en) | Genetically modified bacteria and uses thereof for the inducible expression of a nucleic sequence of interest |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA IL JP SG US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2247805 Country of ref document: CA Kind code of ref document: A Ref document number: 2247805 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997908090 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997908090 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09142648 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997908090 Country of ref document: EP |